BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 33040403)

  • 21. A non-peptide receptor inhibitor with selectivity for one of the neutrophil formyl peptide receptors, FPR 1.
    Cevik-Aras H; Kalderén C; Jenmalm Jensen A; Oprea T; Dahlgren C; Forsman H
    Biochem Pharmacol; 2012 Jun; 83(12):1655-62. PubMed ID: 22410002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dipeptide HCH6-1 inhibits neutrophil activation and protects against acute lung injury by blocking FPR1.
    Yang SC; Chang SH; Hsieh PW; Huang YT; Ho CM; Tsai YF; Hwang TL
    Free Radic Biol Med; 2017 May; 106():254-269. PubMed ID: 28232203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Lipidated Peptidomimetic Lau-((S)-Aoc)-(Lys-βNphe)6-NH2 Is a Novel Formyl Peptide Receptor 2 Agonist That Activates Both Human and Mouse Neutrophil NADPH Oxidase.
    Holdfeldt A; Skovbakke SL; Winther M; Gabl M; Nielsen C; Perez-Gassol I; Larsen CJ; Wang JM; Karlsson A; Dahlgren C; Forsman H; Franzyk H
    J Biol Chem; 2016 Sep; 291(38):19888-99. PubMed ID: 27422818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The annexin I sequence gln(9)-ala(10)-trp(11)-phe(12) is a core structure for interaction with the formyl peptide receptor 1.
    Movitz C; Brive L; Hellstrand K; Rabiet MJ; Dahlgren C
    J Biol Chem; 2010 May; 285(19):14338-45. PubMed ID: 20220135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mechanism for activation of the neutrophil NADPH-oxidase by the peptides formyl-Met-Leu-Phe and Trp-Lys-Tyr-Met-Val-Met differs from that for interleukin-8.
    Fu H; Bylund J; Karlsson A; Pellmé S; Dahlgren C
    Immunology; 2004 Jun; 112(2):201-10. PubMed ID: 15147563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MAP kinases in regulation of NOX activity stimulated through two types of formyl peptide receptors in murine bone marrow granulocytes.
    Filina Y; Gabdoulkhakova A; Rizvanov A; Safronova V
    Cell Signal; 2022 Feb; 90():110205. PubMed ID: 34826588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones.
    Schepetkin IA; Kirpotina LN; Khlebnikov AI; Cheng N; Ye RD; Quinn MT
    Biochem Pharmacol; 2014 Dec; 92(4):627-41. PubMed ID: 25450672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The N-formylpeptide receptor (FPR) and a second G(i)-coupled receptor mediate fMet-Leu-Phe-stimulated activation of NADPH oxidase in murine neutrophils.
    Lavigne MC; Murphy PM; Leto TL; Gao JL
    Cell Immunol; 2002; 218(1-2):7-12. PubMed ID: 12470609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of neutrophil migration in mice by mouse formyl peptide receptors 1 and 2 dual agonist: indication of cross-desensitization in vivo.
    Sogawa Y; Ohyama T; Maeda H; Hirahara K
    Immunology; 2011 Mar; 132(3):441-50. PubMed ID: 21039475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel receptor cross-talk between the ATP receptor P2Y2 and formyl peptide receptors reactivates desensitized neutrophils to produce superoxide.
    Önnheim K; Christenson K; Gabl M; Burbiel JC; Müller CE; Oprea TI; Bylund J; Dahlgren C; Forsman H
    Exp Cell Res; 2014 Apr; 323(1):209-217. PubMed ID: 24491917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutrophil NADPH-oxidase activation by an annexin AI peptide is transduced by the formyl peptide receptor (FPR), whereas an inhibitory signal is generated independently of the FPR family receptors.
    Karlsson J; Fu H; Boulay F; Dahlgren C; Hellstrand K; Movitz C
    J Leukoc Biol; 2005 Sep; 78(3):762-71. PubMed ID: 15951351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reactivation of desensitized formyl peptide receptors by platelet activating factor: a novel receptor cross talk mechanism regulating neutrophil superoxide anion production.
    Forsman H; Önnheim K; Andréasson E; Christenson K; Karlsson A; Bylund J; Dahlgren C
    PLoS One; 2013; 8(3):e60169. PubMed ID: 23555913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition.
    Kirpotina LN; Khlebnikov AI; Schepetkin IA; Ye RD; Rabiet MJ; Jutila MA; Quinn MT
    Mol Pharmacol; 2010 Feb; 77(2):159-70. PubMed ID: 19903830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and characterization of fMLF-mimicking AApeptides.
    Hu Y; Cheng N; Wu H; Kang S; Ye RD; Cai J
    Chembiochem; 2014 Nov; 15(16):2420-6. PubMed ID: 25224835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NOX2-Dependent Reactive Oxygen Species Regulate Formyl-Peptide Receptor 1-Mediated TrkA Transactivation in SH-SY5Y Cells.
    Castaldo M; Zollo C; Esposito G; Ammendola R; Cattaneo F
    Oxid Med Cell Longev; 2019; 2019():2051235. PubMed ID: 31871542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The proteolytically stable peptidomimetic Pam-(Lys-βNSpe)6-NH2 selectively inhibits human neutrophil activation via formyl peptide receptor 2.
    Skovbakke SL; Heegaard PM; Larsen CJ; Franzyk H; Forsman H; Dahlgren C
    Biochem Pharmacol; 2015 Jan; 93(2):182-95. PubMed ID: 25462815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peptide length and folding state govern the capacity of staphylococcal β-type phenol-soluble modulins to activate human formyl-peptide receptors 1 or 2.
    Kretschmer D; Rautenberg M; Linke D; Peschel A
    J Leukoc Biol; 2015 Apr; 97(4):689-97. PubMed ID: 25724390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipoxin A(4) metabolites/analogues from two commercial sources have no effects on TNF-alpha-mediated priming or activation through the neutrophil formyl peptide receptors.
    Forsman H; Dahlgren C
    Scand J Immunol; 2009 Oct; 70(4):396-402. PubMed ID: 19751275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The non-steroidal anti-inflammatory drug piroxicam blocks ligand binding to the formyl peptide receptor but not the formyl peptide receptor like 1.
    Stenfeldt AL; Karlsson J; Wennerås C; Bylund J; Fu H; Dahlgren C
    Biochem Pharmacol; 2007 Oct; 74(7):1050-6. PubMed ID: 17692291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitocryptide-2: Identification of Its Minimum Structure for Specific Activation of FPR2-Possible Receptor Switching from FPR2 to FPR1 by Its Physiological C-terminal Cleavages.
    Marutani T; Nishino K; Miyaji T; Kamada K; Ohura K; Kiso Y; Mukai H
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.